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Abstract
Background: Mitochondrial dysfunction induces insulin resistance in myocytes via a reduction of insulin receptor substrate-1
(IRS-1) expression. However, the effect of mitochondrial dysfunction on insulin sensitivity is not understood well in
hepatocytes. Although research has implicated the translational repression of target genes by endogenous non-coding
microRNAs (miRNA) in the pathogenesis of various diseases, the identity and role of the miRNAs that are involved in the
development of insulin resistance also remain largely unknown.
Methodology: To determine whether mitochondrial dysfunction induced by genetic or metabolic inhibition causes insulin
resistance in hepatocytes, we analyzed the expression and insulin-stimulated phosphorylation of insulin signaling
intermediates in SK-Hep1 hepatocytes. We used qRT-PCR to measure cellular levels of selected miRNAs that are thought to
target IRS-1 39 untranslated regions (39UTR). Using overexpression of miR-126, we determined whether IRS-1-targeting
miRNA causes insulin resistance in hepatocytes.
Principal Findings: Mitochondrial dysfunction resulting from genetic (mitochondrial DNA depletion) or metabolic inhibition
(Rotenone or Antimycin A) induced insulin resistance in hepatocytes via a reduction in the expression of IRS-1 protein. In
addition, we observed a significant up-regulation of several miRNAs presumed to target IRS-1 39UTR in hepatocytes with
mitochondrial dysfunction. Using reporter gene assay we confirmed that miR-126 directly targeted to IRS-1 39UTR.
Furthermore, the overexpression of miR-126 in hepatocytes caused a substantial reduction in IRS-1 protein expression, and
a consequent impairment in insulin signaling.
Conclusions/Significance: We demonstrated that miR-126 was actively involved in the development of insulin resistance
induced by mitochondrial dysfunction. These data provide novel insights into the molecular basis of insulin resistance, and
implicate miRNA in the development of metabolic disease.
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Introduction
Insulin resistance is defined as the decreased responsiveness of
target tissues to ordinary levels of insulin and plays a central role in
the development of metabolic disorders such as type 2 diabetes,
hypertension, and dyslipidemia [1,2]. A number of studies have
provided support for the hypothesis that genetic or functional
impairments in mitochondria are involved in the development of
insulin resistance [3,4]. Cellular oxidative capacity, which mostly
depends on mitochondrial function, is directly correlated with
insulin sensitivity in skeletal muscles [5,6,7], and reduced
mitochondria activity has been observed in patients with obesity
and type 2 diabetes [8,9,10]. Although, several investigations
demonstrated that skeletal muscle oxidative capacity and mito-
chondrial function are not a primary factor for insulin sensitivity in
obese subjects [11,12,13,14], emerging evidence support that
mitochondrial dysfunction may play an important role in the
pathogenesis of insulin resistance and type 2 diabetes [15,16,17].
Recently, it has been suggested that mitochondrial dysfunction
induced by inhibitors of mitochondrial function or depletion of
mitochondrial DNA (mtDNA) causes insulin resistance in
myocytes through a reduction in the expression of insulin receptor
substrate (IRS)-1, a protein with a pivotal role in the insulin
signaling cascade [18,19].
IRS-1 is a key molecule in insulin signaling, and is involved in
signal transduction between the insulin receptor and phosphoino-
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17343sitide 3-kinase (PI3K)[20]. Several lines of evidence suggest that a
reduction in IRS-1 protein plays an important role in the
development of insulin resistance and type 2 diabetes. IRS-1 is
decreased in skeletal muscle and liver of animal models established
for insulin resistance and type 2 diabetes, such as ob/ob mice
[21,22] and Zucker fatty rats [23]. Studies have also reported
decreased IRS-1 expression in the skeletal muscle of patients with
diabetes, and concluded that this could represent a marker for the
risk of insulin resistance [24,25,26,27]. However, the molecular
mechanism underlying the reduction of IRS-1 expression in
muscle and liver under conditions of mitochondrial dysfunction
remains largely unknown.
MicroRNAs (miRNAs) are endogenous small non-coding RNAs
that act as posttranscriptional regulators [28]. Mature miRNAs
hybridize to partially complementary binding sites that are
typically localized in the 39 untranslated regions (39UTR) of
target mRNAs [29]. This property allows a single miRNA
sequence to have multiple target sites on various mRNAs. Upon
binding, the miRNA initiates a pathway that either degrades the
transcripts or suppresses its translation [29]. Although the target
genes and biological functions of individual miRNAs remain
largely unknown, it has been suggested that miRNAs have diverse
functions in both normal and pathological states [28]. Recent
research has established that unregulated miRNAs expression is
implicated in defective insulin secretion, diabetic kidney and heart
disease [30]. However, no previous study has investigated the
involvement of miRNAs in metabolic disorders, in particular the
development of insulin resistance.
Figure 1. Effect of mtDNA depletion induced by EtBr on insulin signaling. SK-Hep1 hepatocytes depleted of mtDNA was prepared by EtBr
treatment for 2 weeks. Cells were preincubated in the absence or presence of insulin (100 nM for 20 min) and total cell lysates (15 mg protein) were
subjected to 8% SDS-PAGE. (A) The expression (IRS-1, Akt2, and GSK3b) and phosphorylation (pIRS-1, pAkt2, and pGSK3b) of insulin signaling
intermediates were analyzed by immunoblot. (B) The immunoblot intensities for IRS-1/b-Actin (IRS-1) and insulin-stimulated pIRS-1/b-Actin (pIRS-1)
were quantified by densitometry and expressed in relative ratio where the intensity of normal control was set to one. (C–D) The immunoblot
intensities for pAkt2/Akt2 and pGSK3b/GSK3b were quantified by densitometry and expressed in relative ratio. The intensity of normal control was set
to one. (E) Cellular glycogen contents were analyzed by spectrophotometry (570 nm) with OxiRed probe. Values are expressed as means 6 SEM from
at least five independent experiments.*, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0017343.g001
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dysfunction resulting from genetic or metabolic inhibition
provoked insulin resistance via a decrease in the expression of
IRS-1. Furthermore, we found that mitochondrial dysfunction
induced the expression of several miRNAs thought to target the
IRS-1 39UTR and that miR-126 was actively involved in the
development of insulin resistance. Our findings in hepatocytes
reveal a novel mechanism for the development of insulin resistance
by providing the first direct evidence that miR-126 mediates the
repression of IRS-1 expression in mitochondrial dysfunction.
Results
Hepatocytes depleted of mtDNA were prepared by exposing
SK-Hep1 hepatocytes to a low dose of ethidium bromide (EtBr,
0.2 mg/ml) for two weeks, as described previously for myocytes
[18]. As shown in Figure S1, treatment with EtBr depleted
mtDNA without altering nuclear DNA, and provoked mitochon-
drial dysfunction. To determine whether mitochondrial dysfunc-
tion induced by mtDNA depletion causes insulin resistance in
hepatocytes, we analyzed the expression and insulin-stimulated
phosphorylation of insulin signaling intermediates, such as IRS-1,
Akt2, and glycogen synthase kinase-3b (GSK3b), in the mtDNA-
depleted SK-Hep1 hepatocytes. We observed about 90%
reduction in the expression of IRS-1 in the cells depleted of
mtDNA by EtBr treatment (Figure 1A-B). As expected, mtDNA
depletion significantly reduced the phosphorylation of IRS-1 and
its substrate, Akt2 (Figure 1B–C). We also found a significant
reduction in the insulin-stimulated phosphorylation of GSK3b,a
substrate of Akt2, in the mtDNA-depleted hepatocytes compared
to control hepatocytes (Figure 1D). In addition, cellular glycogen
contents in the presence or absence of insulin were analyzed in the
control and mtDNA-depleted cells (Figure 1E). As we expected,
insulin significantly increased glycogen contents in control cells.
However, the depletion of mtDNA by EtBr significantly reduced
basal glycogen content as compared to control. Moreover, insulin-
stimulated glycogen synthesis was almost completely disappeared
in mtDNA-depleted hepatocytes (Figure 1E). These findings
clearly indicate that mitochondrial dysfunction resulting from
mtDNA depletion induces the development of insulin resistance in
hepatocytes through a reduction in the expression of IRS-1.
We then investigated whether mitochondrial dysfunction
resulting from metabolic inhibitors, such as Rotenone (an inhibitor
of electron transfer from complex I to ubiquinone) and Antimycin
A (an inhibitor of complex III), causes impairment of insulin
signaling in SK-Hep1 hepatocytes. We observed an almost
complete loss of functional mitochondria in the hepatocytes
treated with Rotenone or Antimycin A (Figure S2), whereas the
Figure 2. Effect of mitochondrial metabolic inhibitors on insulin signaling. For mitochondrial metabolic inhibition, hepatocytes were
treated with Rotenone (0.1 mM) or Antimycin A (20 mM) for 18 h. Cells were incubated in the absence or presence of insulin (100 nM for 20 min) and
total cell lysates (15 mg protein) were subjected to 8% SDS-PAGE. (A) The expression (IRS-1, Akt2, and GSK3b) and phosphorylation (pIRS-1, pAkt2,
and p GSK3b) of insulin signaling intermediates were analyzed by immunoblot. (B) The immunoblot intensities for IRS-1/b-Actin (IRS-1) and insulin-
stimulated pIRS-1/b-Actin (pIRS-1) were quantified by densitometry and expressed in relative ratio where the intensity of normal control was set to
one. (C–D) The immunoblot intensities for pAkt2/Akt2 and pGSK3b/GSK3b were quantified by densitometry and expressed in relative ratio. The
intensity of normal control was set to one. Values are expressed as means 6 SEM from at least five independent experiments.***, P,0.001.
doi:10.1371/journal.pone.0017343.g002
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(data not shown). Interestingly, treatment with Rotenone or
Antimycin A caused a significant reduction in the expression of
IRS-1, whereas the expression of both Akt2 and GSK3b remained
unaffected as compared to control (Figure 2A–B). Both inhibitors
caused a significant reduction in the insulin-stimulated phosphor-
ylation of IRS-1, Akt2, and GSK3b (Figure 2B–D). These findings
suggest that mitochondrial dysfunction secondary to metabolic
inhibition induces the development of insulin resistance in
hepatocytes by decreasing the expression of IRS-1.
Although mitochondrial dysfunction provoked a substantial
decline of IRS-1 mRNA as shown in Figure 3A–B, posttranscrip-
tional repression of IRS-1 should not be excluded. Therefore, to
determine whether miRNA induces repression of IRS-1 expres-
sion posttranscriptionally, we selected several miRNAs targeting
IRS-1 and measured cellular levels of these miRNAs in
hepatocytes with dysfunctional mitochondria. Although mitochon-
drial dysfunction causes numerous changes in the expression of
miRNAs in SK-Hep1 cells, we initially selected miRNAs
presumably targeting a segment of IRS-1 39UTR (within 500
nucleotides from the stop codon) by TargetScan, MiBase, and
PicTar analysis. These analyses revealed that about 70 miRNAs
presumably targeting this region of IRS-1 39UTR. Subsequently,
as shown in Table S1, we selected 11 miRNAs for the next
experiments according to its targeting score to IRS-1 39UTR, as
well as quality and quantity of the results from qRT-PCR analysis.
Although it has been reported that miR-145 targets IRS-1 in colon
cancer cells [31], we excluded miR-145 in this study because of its
low expression level. Interestingly, mtDNA depletion significantly
(more than 2-fold, P,0.05) increased the levels of several of these
miRNAs including miR-27a, miR-27b, miR-30e, and miR-126,
whereas the levels of other selected miRNAs remained unaffected
(Figure 4A). In experiments in which mitochondrial dysfunction
was induced by Rotenone (Figure 4B) or Antimycin A (Figure 4C),
a significant increase in the levels of all of the selected miRNAs
was observed, with the exception of miR-7. Tunicamycin is well
known to induce endoplasmic reticulumn (ER) stress in various
cells including SK-Hep1 hepatocytes. Although treatment with
tunicamycin (2 mg/ml) induced ER stress assessed by phosphor-
ylation of eIF2a (Figure S3), tunicamycin resulted in no significant
change in the levels of any of the 11 selected miRNAs (Figure 4D)
or the expression of IRS-1 (Figure S3). In addition, the levels of
miRNAs such as miR-137, miR-663, miR-1231, miR-1246, and
miR-1287, which are not targeting IRS-1 39UTR, were not
affected by mitochondrial dysfunction (data not shown). This result
indicates that mitochondrial dysfunction increases the level of
several miRNAs that are predicted to target IRS-1 39UTR, thus
potentially implicating miRNAs in the development of insulin
resistance.
Research findings have suggested that these up-regulated
miRNAs may be translational repressors of IRS-1 expression,
and that they may be involved in the development of insulin
resistance. Although we selected miRNAs that are thought to
target IRS-1 39UTR, most of them have not yet been validated for
whether they actually repress IRS-1 expression. Recently, Zhang
et al. [32] found that miR-126 inhibited cell cycle progression in
cancer cells via the targeting of IRS-1 39UTR. We therefore
selected miR-126 for further investigation of its functional
relevance in the development of insulin resistance. To determine
whether miR-126 directly regulates the expression of IRS-1 in SK-
Hep1 hepatocytes, we set up an assay in which 414 nt 39UTR of
the IRS-1 gene, which contains miR-126 binding site (Figure 5A–
B), was inserted downstream of a luciferase open reading frame
(IRS1 3Uwt). A mutated 39UTR of the IRS-1 gene (IRS1 3Umut),
which lacks miR-126 binding site, was used as a control
(Figure 5B). Plasmid DNA of each pGL3-promoter-based
39UTR reporter (IRS1-3Uwt or IRS1-3Umut) was cotransfected
with the indicated concentration of empty plasmid (pSilence6.1) or
miR126 expression plasmid into SK-Hep1 hepatocytes. We found
that luciferase activity with IRS1-3Uwt was significantly inhibited
by miR-126 in a dose-dependent manner, whereas luciferase
activity with IRS1-3Umut was not (Figure 5C). These data suggest
that miR-126 directly targets IRS-1 39UTR and suppresses IRS-1
expression at the posttranscriptional level.
To confirm that IRS-1 is a target gene of miR-126 in
hepatocytes, we transfected SK-Hep1 cells with empty plasmid
or miR-126 expression plasmid, and investigated whether
induction of miR-126 directly represses IRS-1 expression. As
shown in Figure 6, the overexpression of miR-126 resulted in a
substantial reduction in the level of IRS-1 protein with no
apparent change in the level of IRS-1 mRNA, thereby indicating
the posttranscriptional repression of IRS-1 expression by miR-126.
However, the protein levels of Akt2 and GSK3b remained
unaffected (Figure 6A–B). We also examined whether miR-126
could induce posttranslational degradation of IRS-1 in SK-Hep1
cells (Figure 6C). Cycloheximide, an inhibitor of peptidyl
transferase in eukaryotic ribosome, is used for the analysis of
IRS-1 degradation rate by blocking de novo synthesis of proteins.
Figure 3. Transcriptional inhibition of IRS-1 in hepatocytes
with dysfunctional mitochondria. SK-Hep1 hepatocytes were
treated with vehicle, EtBr (0.2 mg/ml, 2 week), Rotenone (0.1 mM,
18 h), or Antimycin A (20 mM, 18 h), and the expression levels of IRS-1,
Akt2, GAPDH, and b-Actin were measured by (A) RT-PCR and (B) qRT-
PCR. The fold changes are expressed in relative ratio where the intensity
of b-Actin was set to one. All results represent mean 6 SEM from three
independent experiments. ***, P,0.001 vs Control.
doi:10.1371/journal.pone.0017343.g003
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sion of IRS-1, the degradation rate of IRS-1 was not affected by
miR-126. Therefore, it is suggested that the forced expression of
miR-126 in hepatocytes does not affect the expression of IRS-1
posttranslationally.
Next, we analyzed expression and insulin-stimulated phosphor-
ylation of insulin signaling intermediates in the hepatocytes
transfected with miR-126 expression plasmid (Figure 7). The
expression of IRS-1 was significantly reduced by 75% after miR-
126 overexpression, whereas expression of Akt2 and GSK3b was
not affected. As expected, the overexpression of miR-126
significantly reduced insulin-stimulated phosphorylation of IRS-1
and its downstream kinases, Akt2 and GSK3b in hepatocytes, and
this effect was mainly due to a reduction in the expression of IRS-1
(Figure 7B–D). In addition, we determined how the overexpression
of miR-126 affects cellular glycogen contents in the presence or
absence of insulin (Figure 7E). In control cells, insulin significantly
increased glycogen contents in hepatocytes. However, glycogen
content in miR-126-overexpressed hepatocytes was significantly
reduced as compared to control. Moreover, induction of miR-126
abolished insulin-stimulated glycogen synthesis (Figure 7E). Taken
together, these data clearly indicate that the induction of miR-126
causes insulin resistance in hepatocytes through a reduction in the
expression of IRS-1.
Discussion
Mitochondrial dysfunction is associated with the development of
insulin resistance and diabetes [3,4,16]. In the present study, we
demonstrated that mitochondrial dysfunction resulting from
genetic or metabolic inhibition induced the development of insulin
resistance in hepatocytes via a reduction of IRS-1 expression. This
result is in accordance with previous findings in myocytes that a
reduced expression of IRS-1 is involved in the development of
insulin resistance [18,19]. Recent work in myocytes has revealed
that mitochondrial retrograde signals inhibit the expression of
IRS-1 at the transcriptional level by activating c-Jun N-terminal
kinase (JNK) and p38 mitogen-activated protein kinase (MAPK),
which in turn up-regulates an IRS-1 transcriptional suppressor,
ATF3 [19]. Although the regulation of IRS-1 expression occurs at
the transcriptional level under conditions of mitochondrial
dysfunction, posttranscriptional regulation also occurs. For
example, mitochondrial dysfunction activates certain stress
kinases, such as IkB kinaseb and JNK. These are well-known
serine kinases that phosphorylate IRS-1 at serine residues, leading
to decreased metabolic signaling by increasing IRS-1 degradation
and serine phosphorylation [16]. Although coordinated alteration
in expression of skeletal muscle miRNAs relates to insulin
resistance in diabetes [33], the involvement of miRNAs in
posttranscriptional repression of IRS-1 are largely unknown,
especially in mitochondrial dysfunction,
The fact that no previous studies have investigated the role of
miRNAs in insulin signaling accounts for the lack of research into
their potential as therapeutic targets for metabolic disease. We
hypothesized that certain miRNAs may participate in the
development of insulin resistance induced by mitochondrial
dysfunction. We observed a significant increase in the expression
of several presumed IRS-1–39UTR-targeting miRNAs in hepato-
cytes with dysfunctional mitochondria. In particular, we found
that ectopic expression of miR-126, an induced IRS-1-targeting
miRNAs, represses translation of IRS-1 without altering the
mRNA level of IRS-1, which subsequently leads to insulin
resistance in hepatocytes. Expression of miR-126 is decreased in
various cancer cells, and it has previously been regarded as a cell
Figure 4. Expression of miRNAs presumably targeting IRS-1 39UTR. SK-Hep1 hepatocytes were treated with (A) EtBr (0.2 mg/ml, 2 week), (B)
Rotenone (0.1 mM, 18 h), (C) Antimycin A (20 mM, 18 h), or (D) Tunicamycin (2 mg/ml, 18 h), and the expression levels of miRNAs that predicted to
target IRS-1 39UTR were measured by qRT-PCR. The fold changes are expressed in relative ratio where U6 intensity set to one.
doi:10.1371/journal.pone.0017343.g004
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p85b [35]. In the present study, we have unveiled a new role of
miR-126 as a metabolic regulator. Further, several other miRNAs
predicted to target the IRS-1 39UTR were induced by mitochon-
drial dysfunction in a similar fashion to miR-126, it is still open
questions whether these miRNAs directly target the 39UTR and
repress IRS-1 expression. In addition, the expression of miRNA
target genes can be modulated by altering the identity or the
concentration of the miRNAs within cells [36]. Therefore, the
combinational binding of different miRNAs on non-overlapping
binding sites of IRS-1 39UTR may synergistically potentiate the
miRNA-induced repression of IRS-1. The discovery that miR-126
regulates insulin signaling provides novel insights into the
molecular basis underlying mitochondrial dysfunction-derived
pathogenesis of insulin resistance, and implicates miRNAs in
metabolic diseases.
Here, we propose a possible mechanism for how miRNA
participates in the development of insulin resistance under
conditions of mitochondrial dysfunction. Mitochondrial dysfunc-
tion results in the generation of various retrograde signals to the
nucleus, as described initially in myocytes [37]. These retrograde
signals activate several kinases and transcriptional factors,
resulting in the suppression of IRS-1 transcription and induction
of IRS-1 degradation [19]. However, the results of present study
suggest that some of the transcriptional factors that are affected
by this retrograde signaling may activate the production and
processing of miRNAs targeting the IRS-1 39UTR, thereby
leading to IRS-1 posttranscriptional repression and subsequent
insulin resistance. Further analysis of which metabolic signals and
transcriptional factors are involved and how they work in
miRNA-mediated insulin resistance will be the next step of
research.
In conclusion, we have demonstrated that mitochondrial
dysfunction induced by mtDNA depletion or metabolic inhibition
causes the development of insulin resistance in hepatocytes
through a reduction in the expression of IRS-1. We found that
mitochondrial dysfunction significantly up-regulated the expres-
sion of several miRNAs that are thought to target IRS-1. We
confirmed that miR-126 is a crucial inhibitory factor in insulin
signal transduction under conditions of mitochondrial dysfunction.
Consequently, these data provide a novel mechanism for the
development of insulin resistance, and serve as a foundation for
further studies designed to explore the functional relevance of
miRNAs in diabetes and metabolic syndrome.
Materials and Methods
Cell culture and induction of mitochondrial dysfunction
SK-Hep1 hepatocytes (ATCC HTB-52) were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal
bovine serum (FBS). For mtDNA depletion, cells were incubated
with EtBr (0.2 mg/ml) and uridine (50 mg/ml) for 2 weeks in
DMEM with 10% FBS. Under these experimental conditions,
mtDNA was depleted to ,10% of normal. For mitochondrial
metabolic inhibition, cells were treated with Rotenone (0.1 mM) or
Antimycin A (20 mM) for 18 h. Hepatocytes were deprived of
serum for 5 h prior to all experimental analysis.
Genomic DNA extraction and polymerase chain reaction
(PCR)
Total cellular DNA was extracted according to the manufac-
turer’s instructions by using DNeasy Tissue kit (Qiagen). PCR and
qRT-PCR was performed in LightCyclerH480 (Roche-Applied
Science) using SYBR-Green PCR Master Mix according to
manufacturer’s instructions (Qiagen) with the specific primers
listed in Table S1.
Staining of functional mitochondria
SK-Hep1 hepatocytes were incubated with the active mito-
chondrial-specific fluorescent dye, MitoTracker Orange CM-
H2TMRos (Molecular Probes, Eugene, OR), for 15 min at 37uC
and washed three times with cold PBS. The cells were visualized
and photographed in a fluorescence microscope (Leica, Germany).
The fluorescent intensity reflects the integrity of mitochondrial
function [38].
Figure 5. Targeting site of miR-126 in the 39UTR of IRS-1 and
measurement of its binding by reporter gene assay. (A) Seed
sequence of miR-126 is predicted to target IRS-1 39UTR. (B) For reporter
gene assay, 414 nt-long 39UTR of the IRS-1 gene was inserted
downstream of a luciferase open reading frame (IRS1-3Uwt). As a
control, a mutated 39UTR of IRS-1 gene (IRS1 3Umut) lacking the miR-
126 binding site was used. (C) IRS1-3Uwt (closed column) or IRS1-
3Umut (open column) construct was cotransfected with the indicated
concentration of empty plasmid (Control) or miR-126 expression
plasmid (miR-126) into SK-Hep1 hepatocytes. Reporter gene assay
were performed using a Dual-luciferase assays kit as described in
Methods. The relative luciferase activities were plotted against that of
control, which is set as 100%. Values are expressed as means 6 SEM
from four independent experiments. *, P,0.05; **, P,0.01 vs IRS1-
3Umut.
doi:10.1371/journal.pone.0017343.g005
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The cellular ATP was measured by using a somatic cell ATP
assay kit (Sigma, Louis, MO) as described in the manufacturer’s
procedure.
RNA preparation and quantitative real-time RT-PCR (qRT-
PCR)
Total cellular RNA was extracted using miRNeasy Mini kit
(Qiagen, Valencia, CA). For qRT-PCR, total RNAs were reverse
transcribed into cDNAs with miScript Reverse Transcription kit
(Qiagen) and amplified with specific primers (Bionics, Seoul,
Korea) listed in Table S1. qRT-PCR was carried out in
LightCyclerH480 (Roche-Applied Science, Mannheim, Germany)
using SYBR-Green PCR Master Mix according to manufacturer’s
instructions (Qiagen).
Overexpression of miR-126 and reporter gene assay
Plasmids (pSilencer4.1CMV-puro, Ambion) expressing miR-
126 pre-miRNA (flanking upstream and downstream 30–50 nt) for
overexpression of miR-126 was produced as described previously
[32] and transfected to SK-Hep1 hepatocytes with Lipofectamine
2000. For luciferase assay, DNA fragments (414 nt) of IRS-1
39UTR containing predicted miR-126 binding site (IRS1-3Uwt)
were cloned into the pGL3-promoter plasmid (Promega) and the
mir-126 binding sites were replaced with an 4 nt fragment to
produce mutated 39UTR pGL3 report plasmids (IRS1-3Umut)a s
described [32]. Luciferase assays were performed with the Dual
luciferase reporter system (Promega) in accordance with manu-
facturer’s instructions. Briefly, SK-Hep1 cells were plated the day
before transfection onto 12-well plates and grown to an
approximate 70% confluence. The cells were cotransfected with
IRS1-3Uwt or 3Umut and miR-126 expression plasmid together
with pRL-SV40 for constitutive expression of Renilla luciferase as
an internal control. At 48 h posttransfection, the cells were lysed
and subjected to the measurement of the firefly and Renilla
luciferase activities on a Lumat LB 9507 luminometer (EGG,
Stuttgart, Germany). The ratio of firefly luciferase activity to
Renilla luciferase activity was presented in arbitrary units as the
relative luciferase activities.
Glycogen Assay
Glycogen contents in the cultured cells were analyzed with
Glycogen Assay Kit (BioVision, Mountain View, CA) by
spectrophotometry (570 nm) with OxiRed probe according to
manufacturer’s suggestion.
Gel Electrophoresis and Immunoblotting
Cell lysates solubilized in Laemmli solution were subjected to
SDS-PAGE on 8 or 10% resolving gels and immunoblotting as
Figure 6. Effect of miR-126 on expression of IRS-1. SK-Hep1 hepatocytes were transfected with the indicated concentration of empty plasmid
(Control) or miR-126 expression plasmid (miR-126). (A) mRNA level was analyzed 24 h of transfection, whereas immunoblot analysis was conducted
after 72 h of transfection. These are representative results from five independent experiments. (B) Expressions of IRS-1 were analyzed by qRT-PCR
(open column) and immunoblotting (closed column). The mRNA and protein of IRS-1 were expressed in relative ratio, where the intensity of empty
plasmid alone was set to one. (C) SK-Hep1 hepatocytes were transfected with 3 mg/ml of empty plasmid (Control, open column) or miR-126
expression plasmid (miR-126, closed column). After 60 h of transfection, cells were treated with cycloheximide (50 mg/ml for 12 h) and total cell
lysates (15 mg protein) were subjected to 8% SDS-PAGE. The protein levels of IRS-1 were analyzed by densitometry and expressed in relative ratio,
where the intensity of 0 h was set to one. Values are expressed as means 6 SEM from at least five independent experiments. **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0017343.g006
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Upstate (Lake Placid, NY) and antibody against phosphor IRS-1
was from Invitrogen (Carlsbad, CA). All other antibodies were
obtained from Cell Signaling (Beverly, MA). Proteins were
visualized using enhanced chemiluminescent substrate kit (NEN
Life Science Products). Immunoblot intensities were quantitated
by densitometry using an analytical scanning system (Molecular
Dynamics Inc., Sunnyvale, CA).
Database and Statistical analysis
We computationally screened miRNAs targeting IRS-1 39UTR
with TargetScan (http://www.targetscan.org/index.html) and
miRBase (http://microrna.sanger.ac.uk). Results were expressed
as the mean 6 SEM. Where applicable, the significance of
difference was analyzed using Student’s t test for unpaired data.
Supporting Information
Figure S1 Mitochondrial dysfunction induced by EtBr.
(A) Genomic DNA and mRNA were isolated from control or EtBr-
treated SK-Hep1 hepatocytes, and mtDNA-encoded genes such as
cytochrome c oxidase subunit I (COX-I) and subunit II (COX-II),
and nuclear DNA-encoded gene such as cytochrome c oxidase
subunit IV (COX-IV) were amplified by RT-PCR and qRT-PCR.
Figure 7. Effect of miR-126 on insulin signaling. SK-Hep1 hepatocytes were transfected with 3 mg/ml of empty plasmid (Control) or miR-126
expression plasmid (miR-126). After 72 h of transfection, cells were preincubated in the absence or presence of insulin (100 nM for 20 min) and total
cell lysates (15 mg protein) were subjected to 8% SDS-PAGE. (A) The expression (IRS-1, Akt2, and GSK3b) and phosphorylation (pIRS-1, pAkt2, and
pGSK3b) levels of insulin signaling intermediates were analyzed by immunoblot. (B) The immunoblot intensities for IRS-1/b-Actin (IRS-1) and insulin-
stimulated pIRS-1/b-Actin (pIRS-1) were quantified by densitometry and expressed in relative ratio, where the intensity of normal control was set to
one. (C–D) The immunoblot intensities for pAkt2/Akt2 and pGSK3b/GSK3b were quantified by densitometry and expressed in relative ratio. The
intensity of normal control was set to one. (E) Cellular glycogen contents were analyzed by spectrophotometry (570 nm) with OxiRed probe. Values
are expressed as means 6 SEM from at least five independent experiments. *, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0017343.g007
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intensity of controlwas setto one. (C) Controland EtBr-treated SK-
Hep1 hepatocytes were stained with the active mitochondrial-
specific fluorescent dye, MitoTracker Orange CM-H2TMRos, as
described in Methods. Magnification is , X400. (D) Total cellular
ATP levels were measured by the luciferin/luciferase assay. ATP
content was expressed in arbitrary units where the ATP content
from control cells was set to one. All results represent mean 6 SEM
from three independent experiments. **, P,0.01; ***, P,0.001.
Results: As shown in Figure S1 (A and B), cytochrome oxidase
subunits I (COX-I) and II (COX-II), both encoded only in mtDNA,
were hardly amplified from the genomic DNA and cDNA of the
cells treated with EtBr for 2 weeks. In contrast, nuclear DNA-
encoded genes such as COX-IV and b-actin were detected at
similar levels in both control and EtBr-treated hepatocytes,
indicating that prolonged treatment with EtBr depleted the cellular
contents of mtDNA and its transcripts without altering the nuclear
DNA replication. Next, we measured mitochondrial function with
the active mitochondrial-specific fluorescent dye, MitoTracker
Orange CM-H2TMRos [40,41,42,43]. Since this Mitotracker
localizes in mitochondria in a DYm-dependent manner, the
fluorescentintensityfromlivingcellsthoroughlyreflectstheintegrity
of mitochondrial function. The depletion of mtDNA induced by
EtBr treatment drastically reduced functional mitochondria in the
cell (C). In addition, the depletion of mtDNA significantly reduced
total cellular ATP level as compared to control cells (D). These data
clearly indicates that cellular treatment with EtBr depleted mtDNA
without altering nuclear DNA and provoked mitochondrial
dysfunction in SK-Hep1 hepatocytes.
(TIF)
Figure S2 Inhibition of mitochondrial function by
Rotenone and Antimycin A. For mitochondrial metabolic
inhibition, cells were treated with Rotenone (0.1 mM) or
Antimycin A (10 mM) for 18 h. Hepatocytes were deprived of
serum for 5 h prior to all experimental manipulations. Cells were
stained with the active mitochondrial-specific fluorescent dye,
MitoTracker Orange CM-H2TMRos, as described in Methods.
Magnification is , X400.
(TIF)
Figure S3 Expression of IRS-1 under ER stress induced
by tunicamycin. SK-Hep1 hepatocytes were treated with
vehicle or tunicamycin for 18 hr, and mRNA and protein of
IRS-1 were measured by RT-PCR and immunoblotting, respec-
tively. Phosphorylation of eIF2a (peIF2a) was used for ER stress
marker.
(TIF)
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